TO
Tonmoy009
Community Contributor
Member since 2026
Views28Total number of views
Followers2Total number of followers
Comments0Total number of comments
No bio added yet
No link added
My view on CSL Limited is positive. It’s a high-quality growth stock with strong barriers to entry through its global plasma network.
One stock I find particularly compelling is CSL Limited (ASX: CSL), primarily due to its strong competitive positioning, structural growth drivers, and valuation complexity. From a fundamental perspective, CSL operates in the global plasma therapies and specialty pharmaceuticals market, where demand is relatively inelastic and supported by long-term healthcare trends.Read more
28
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
TO
AU$140.64
4.8% overvalued intrinsic discount
Tonmoy009's Fair Value
Revenue
4.95% p.a.
Profit Margin
9.06%
Future PE
37.47x
Price in 2031
AU$199.2